Circulating KL-6 level at baseline is a predictive indicator for the occurrence of interstitial pneumonia during interferon treatment for chronic hepatitis C

详细信息    查看全文

• 作者：Tokita ; Hajime ; Fukui ; Hideo ; Tanaka ; Akihisa ; Kamitsukasa ; Hiroshi ; Yagura ; Michiyasu ; Harada ; Hideharu ; et. al.
• 关键词：KL-6 ; Surfactant protein A (SP-A) ; Surfactant protein D (SP-D) ; Interferon treatment ; Interstitial pneumonia ; Chronic hepatitis C
• 刊名：Hepatology Research
• 出版年：2003
• 出版时间：June, 2003
• 年：2003
• 卷：26
• 期：2
• 页码：91-97
• 全文大小：206 K

文摘

Interstitial pneumonia (IP) is a serious adverse event of interferon alpha (IFNα) treatment for chronic hepatitis C (CH-C). Among 558 CH-C patients who received IFNα treatment with or without ribavirin between January 1992 and June 2002, six patients (1.1 % ) developed IP, including one patient who developed IP in 1993 and again in 2002. Among the seven cases who contracted IP, at the onset of IP, seven (100 % ), five (71 % ), and two cases (29 % ) had elevated serum levels of KL-6, surfactant protein A (SP-A), and surfactant protein D (SP-D), respectively. Prior to starting IFN treatment (baseline), the serum SP-A and SP-D levels were within the normal range in all seven cases, but the serum KL-6 level was elevated in five of the seven cases, contrasting with that in three of 48 age-adjusted CH-C patients who did not develop IP during IFN treatment (71 vs. 6 % ; P